Drug Topics

SEPTEMBER 7, 2022

Even “THC-free” cannabidiol products may contain trace amounts of THC.

611

611

PharmaVoice

SEPTEMBER 6, 2022

From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.

344

344

Pharmacy Times

SEPTEMBER 9, 2022

Prescription drug monitoring programs have decreased prescription opioids in the United States but resulted in unintended spikes of illegal drug use and heroin-related deaths.

172

172

STAT

SEPTEMBER 8, 2022

At the end of an unusual and dramatic meeting on Wednesday, an independent panel of advisers to the Food and Drug Administration recommended the approval of a new drug to treat people with ALS developed by Amylyx Pharmaceuticals. The vote was 7-2, a substantial margin of support for the Amylyx drug called AMX0035 and a reversal of the same group’s vote against the drug last March.

FDA 145

FDA 145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

SEPTEMBER 9, 2022

Are prescription cap laws for opioids effective for children and teenagers?

579

579

PharmaVoice

SEPTEMBER 6, 2022

With his unique platform, the has built a bridge between patients, physicians and researchers around the world.

290

290

STAT

SEPTEMBER 6, 2022

WASHINGTON — Researchers studying next-generation vaccines to fight an evolving Covid-19 threat are running into problems getting existing vaccines to use in their research. Because Pfizer and Moderna hold the patents for the current vaccines, researchers would likely have to get the companies’ permission to use them for research into products like nasal or pan-coronavirus vaccines.

Vaccines 145

Vaccines 145

Drug Topics

SEPTEMBER 7, 2022

When it comes to the COVID-19 vaccine, independent pharmacies are being set up to fail by federal health partners.

Independent Pharmacies 568

Independent Pharmacies Vaccines 568

PharmaVoice

SEPTEMBER 7, 2022

The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive.

246

246

Pharmacy Times

SEPTEMBER 6, 2022

Analysis shows that over 5 years, the percentage of women without relapse was 89% for those who had hormonal stimulation of the ovaries and 83% for those with ovarian tissue freezing.

139

139

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 8, 2022

Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30% — a clinical trial result that could lead to a better treatment option for patients with advanced disease and strengthen the drug’s commercial outlook. In the study, called TROPICS-02, Trodelvy showed a median overall survival of 14.4 months compared to 11.2 months for comparator chemotherapy.

Chemotherapy 144

Chemotherapy 144

Drug Topics

SEPTEMBER 7, 2022

CBD products range from gummies to tinctures to topical lotions and creams.

530

530

PharmaVoice

SEPTEMBER 6, 2022

As a patient advocate, The Spark Global’s owner is transforming how pharma companies approach patient centricity.

246

246

pharmaphorum

SEPTEMBER 5, 2022

Sam Crowther, founder and CEO of cybersecurity company Kasada, tells us about a recent discovery his company made that revealed tens of thousands of accounts with prescription drug attachments in major online pharmacies had been compromised. While performing analysis for a client of online accounts for sale, Kasada uncovered a new and illegal way bots are being used – to steal pharmacy customers’ accounts and resell prescriptions on a secondary market for in-demand substances, such as Oxyc

Compounding 138

Compounding Controlled Substances 138

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

SEPTEMBER 8, 2022

A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the bile ducts, led to tumor shrinkage of a third or more in 15 of 17 patients with metastatic disease, the company said Wednesday. The results were released in an abstract at the annual meeting of the European Society of Molecular Oncology, where they will be presented in full on Sunday.

143

143

Drug Topics

SEPTEMBER 8, 2022

Addressing patient concerns about cannabidiol can be the key to patient satisfaction.

529

529

PharmaVoice

SEPTEMBER 6, 2022

Real-world data (RWD) from clinical drug registries can and should be used throughout the drug development lifecycle. At all stages, registries ensure that assumptions about the current standard of care are accurate and evidence-based.

246

246

Pharmaceutical Technology

SEPTEMBER 8, 2022

Tetra Bio-Pharma and Cellvera have entered an agreement to jointly develop ARDS-003 as an oral combination therapeutic candidate with 400mg Qifenda (Favipiravir) for Covid-19. A first-in-human drug product, ARDS-003 contains the active pharmaceutical agent, Onternabez. Onternabez is a selective full agonist of the type 2 cannabinoid receptor (CB2R).

Pharmaceutical Companies 132

Pharmaceutical Companies Pharmaceutical Companies Immunization 132

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

SEPTEMBER 8, 2022

Nothing has made the nation’s addiction epidemic more deadly than fentanyl’s infiltration of the drug supply. Yet in more than a dozen states, tools used to detect the ultra-potent synthetic opioid are still classified as drug paraphernalia — making it a crime to possess or distribute them. The practice of “drug-checking” — essentially, testing illicit drugs to see if they contain unknown toxins — has remained controversial even as the crisis of f

139

139

Drug Topics

SEPTEMBER 9, 2022

Software updates in closed-loop systems may lead to better time in range numbers for children with type 1 diabetes.

519

519

PharmaVoice

SEPTEMBER 8, 2022

Supply chain challenges, labor shortages and increased FDA inspections are boosting recall risks — but careful planning can keep companies in the clear.

FDA 245

FDA 245

Pharmacy Times

SEPTEMBER 8, 2022

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

132

132

STAT

SEPTEMBER 5, 2022

By this time next year, if the medical forecasts are correct, I will probably be dead, another casualty of a fatal illness that most people have never heard of: idiopathic pulmonary fibrosis (IPF). This condition has been described by Michael J. Stephen in his 2021 book “Breath Taking” as the “most frustrating and disheartening of all the diseases in pulmonary medicine.

137

137

Drug Topics

SEPTEMBER 9, 2022

Address vaccine hesitancy at your pharmacy to encourage patients and their families to get vaccinated against COVID-19, flu, and more.

Vaccines 503

Vaccines 503

PharmaVoice

SEPTEMBER 6, 2022

The CMO at Kura Oncology, a clinical-stage biopharma company, is charting a new course to deliver on the promise of precision medicine in oncology.

245

245

Pharmacy Times

SEPTEMBER 8, 2022

Patients should discuss efficacy and potential drug interactions with clinicians before use, study authors indicate.

132

132

PhRMA

SEPTEMBER 9, 2022

America leads the world in biomedical innovation today because our system rewards investment in research and discovery of new treatments. Now, with the passage of the Inflation Reduction Act , Dr. Steven Pearson, president of the Institute for Clinical and Economic Review (ICER), coolly admits we will see fewer new cures and treatments and suggests that trade-off is one we need to make.

130

130

Drug Topics

SEPTEMBER 8, 2022

Encouraging outcomes in recent studies have researchers calling for more analysis of the effect of cannabinoids on sleep disorders.

503

503

PharmaVoice

SEPTEMBER 6, 2022

GSK’s medical oncology head is paving the way for patient-driven drug development and more equitable care.

147

147

Pharmacy Times

SEPTEMBER 8, 2022

Pharmacists handle public vaccination efforts and need to assess where patients are on the hesitancy spectrum to provide reliable information.

Vaccines 132

Vaccines 132

STAT

SEPTEMBER 7, 2022

For Illumina, the leading maker of DNA sequencing equipment, there was bad news and worse news Tuesday. The bad news: The European Commission said it was blocking Illumina’s $8 billion acquisition of Grail, a firm focused on the early detection of cancer. The worse news? In its press release on the ruling, Illumina acknowledged that, although it will appeal, that may not prevent the European Commission from forcing it to divest Grail, which it purchased before regulatory approvals were in

128

128

Drug Topics

SEPTEMBER 7, 2022

Keep your pharmacy vaccine-ready for your youngest patients with the most current influenza vaccination information from the American Academy of Pediatrics.

Vaccines 503

Vaccines 503

PharmaVoice

SEPTEMBER 6, 2022

The longtime regulatory pro has used innovative strategies to deliver emerging oncology therapies to patients from her position as head of regulatory affairs at Stemline.

130

130